1. Home
  2. KALV vs TDOC Comparison

KALV vs TDOC Comparison

Compare KALV & TDOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.78

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Teladoc Health Inc.

TDOC

Teladoc Health Inc.

HOLD

Current Price

$6.53

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
TDOC
Founded
N/A
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
KALV
TDOC
Price
$26.78
$6.53
Analyst Decision
Strong Buy
Buy
Analyst Count
5
18
Target Price
$32.60
$7.56
AVG Volume (30 Days)
5.2M
5.0M
Earning Date
07-09-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
80.58
EPS
N/A
N/A
Revenue
$50,000,000.00
$2,406,840,000.00
Revenue This Year
$185.42
$1.19
Revenue Next Year
$59.23
$1.25
P/E Ratio
N/A
N/A
Revenue Growth
495.66
18.41
52 Week Low
$9.83
$4.40
52 Week High
$26.85
$9.77

Technical Indicators

Market Signals
Indicator
KALV
TDOC
Relative Strength Index (RSI) 75.00 54.50
Support Level $14.25 $5.08
Resistance Level $26.85 $7.95
Average True Range (ATR) 0.07 0.35
MACD -0.16 -0.06
Stochastic Oscillator 65.91 29.13

Price Performance

Historical Comparison
KALV
TDOC

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About TDOC Teladoc Health Inc.

Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.

Share on Social Networks: